Current Report Filing (8-k)
10 January 2023 - 12:32AM
Edgar (US Regulatory)
NASDAQ false 0001517022 0001517022
2023-01-09 2023-01-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9,
2023
AKEBIA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-36352 |
|
20-8756903 |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
245 First Street
Cambridge, Massachusetts
|
|
02142 |
(Address of principal executive
offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (617)
871-2098
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
Title of each class
|
|
Trading
symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.00001 per share |
|
AKBA |
|
The
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§ 240.12b-2 of
this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01 |
Regulation FD Disclosure.
|
Spokespersons of Akebia Therapeutics, Inc. (the “Company”) plan to
present the information in the presentation attached hereto as
Exhibit 99.1 (the “Presentation”) at various meetings beginning on
January 9, 2023, including investor and analyst meetings that
coincide with the J.P. Morgan Healthcare Conference.
A copy of the presentation is attached as Exhibit 99.1 to this
Current Report on Form 8-K
and is incorporated herein by reference.
The information in this Current Report on Form 8-K (including Item 7.01 and Exhibit
99.1) shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Exchange Act or the Securities Act of 1933, as amended, except
as expressly set forth by specific reference in such a filing.
By providing the information in Item 7.01 of this Current Report on
Form 8-K, including Exhibit
99.1 hereto, the Company is not making an admission as to the
materiality of any information herein. The information contained in
this Current Report on Form 8-K is intended to be considered in the
context of more complete information included in the Company’s
filings with the SEC and other public announcements that the
Company has made and may make from time to time by press release or
otherwise. The Company undertakes no duty or obligation to update
or revise the information contained in this Current Report on Form
8-K, although it may do so
from time to time as its management believes is appropriate. Any
such updating may be made through the filing of other reports or
documents with the SEC, through press releases or through other
public disclosures.
Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
AKEBIA
THERAPEUTICS, INC. |
|
|
|
|
Date: January 9, 2023 |
|
|
|
By: |
|
/s/ John P. Butler
|
|
|
|
|
|
|
Name: John P.
Butler |
|
|
|
|
|
|
Title:
President and Chief Executive Officer |
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Feb 2023 to Mar 2023
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Mar 2022 to Mar 2023